Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. EDUCATION PROGRAMMES FOR PERSONS WITH TYPE 1 DIABETES USING AN INSULIN PUMP: A SYSTEMATIC REVIEW

    Research output: Contribution to journalReviewResearchpeer-review

  2. Treatment of modifiable risk factors for foot ulceration in persons with diabetes: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update)

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Glucose homeostasis in statin users-The LIFESTAT study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Oral insulin does not alter gut microbiota composition of NOD mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Does Subclinical Hypothyroidism Add Any Symptoms? evidence from a Danish population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fractures and Osteoporosis in Patients With Diabetes With Charcot Foot

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. How Common Is the Rare Charcot Foot in Patients With Diabetes?

    Research output: Contribution to journalLetterResearchpeer-review

  • Kim Henriksen
  • Inger Byrjalsen
  • Per Qvist
  • Henning Beck-Nielsen
  • Gitte Hansen
  • Bente J Riis
  • Hans Perrild
  • Ole Lander Svendsen
  • Jeppe Gram
  • Morten A Karsdal
  • Claus Christiansen
  • BALLET Trial Investigators
View graph of relations
Treatment of patients with perioxisome proliferator-activated receptor-γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator-activated receptor-γ agonists has not been established in a clinical trial. The BALaglitazone glucose Lowering Efficacy Trial aimed to establish the glucose-lowering effects and safety parameters of the perioxisome proliferator-activated receptor-γ partial agonist balaglitazone in diabetic patients on stable insulin therapy.
Original languageEnglish
JournalDiabetes - Metabolism: Research and Reviews (Print Edition)
Volume27
Issue number4
Pages (from-to)392-401
Number of pages10
ISSN1520-7552
DOIs
Publication statusPublished - 2011

    Research areas

  • Aged, Blood Glucose, Body Composition, Bone Density, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Hemoglobin A, Glycosylated, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, PPAR gamma, Quinazolines, Thiazolidinediones, Water-Electrolyte Balance, Weight Gain

ID: 34796416